We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
13
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Completed
8
61.5%
Not yet recruiting
2
15.4%
Recruiting
Terminated
1
7.7%
No approval data available
- The FDA has accepted Echosens' Letter of Intent to qualify liver stiffness measurement by FibroScan® as the first non-invasive surrogate endpoint for MASH clinical trials. - This milestone could replace invasive liver biopsies for patient enrollment and treatment response assessment in MASH drug development programs. - The acceptance is supported by over 5,600 peer-reviewed publications and endorsements from major pharmaceutical companies including Eli Lilly, Boehringer Ingelheim, and Novo Nordisk. - The development has the potential to accelerate drug development by improving trial recruitment and patient retention while reducing patient burden.
